Emphasis on Aggressive Cancer Cells

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Vaccine Development

New Vaccine Technologies Expand the Frontiers of Prevention and Treatment

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Vaccines

Beyond Infectious Disease: Vaccines for Cancer and Chronic Conditions

Pharma's Almanac

LAIs

Seven Biotechs Developing Long-Acting Injectable Drugs

Vedangi Joshi

Nice Insight

In Vivo CAR-T

Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic

Emma Gormlie

Nice Insight

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.; David Alvaro, Ph.D.

Pheast Therapeutics

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac